New Research Confirms No Link Between Maternal mRNA COVID-19 Vaccination and Developmental Disorders in Toddlers

The landscape of maternal health and prenatal care has faced significant scrutiny since the emergence of COVID-19, particularly regarding the safety profile of mRNA vaccination during gestation. A pivotal study presented at the 2026 Pregnancy Meeting of the Society for Maternal-Fetal Medicine (SMFM) has provided comprehensive, long-term data addressing these concerns. According to the research findings, receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not associated with an increased risk of autism or other neurodevelopmental disorders in children. These findings offer critical reassurance to expectant parents and healthcare providers navigating vaccination decisions during the perinatal period.

The study, which evaluated 434 toddlers, serves as a significant addition to the growing body of literature surrounding vaccine safety. By tracking the neurodevelopmental outcomes of children between the ages of 18 and 30 months, researchers have provided a granular look at the potential long-term impacts of prenatal vaccine exposure. The results suggest that the benefits of maternal immunization—which include the protection of the mother from severe illness and the potential passive immunity transferred to the infant—are not offset by adverse developmental outcomes.

The Methodology and Scope of the Investigation

The investigation was spearheaded by researchers within the Maternal-Fetal Medicine Units (MFMU) Network, an initiative funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The study was prospective, multi-center, and observational, conducted between May 2024 and March 2025. This timeframe allowed for the systematic observation of a cohort that reflects the real-world application of vaccination protocols.

To maintain scientific rigor, the researchers employed a matched-pair design. The 434 children included in the study were split evenly: 217 were born to mothers who received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within the 30-day window prior to conception. The control group consisted of 217 children born to mothers who remained unvaccinated during this same period.

The researchers meticulously matched participants to minimize confounding variables. Comparisons were adjusted based on clinical delivery settings, such as hospitals or birth centers, the specific date of delivery, the maternal insurance status, and the racial demographics of the participants. Furthermore, the study design excluded high-risk cases that could skew data, such as pregnancies that ended prior to 37 weeks, multi-fetal gestations, and cases involving infants with major congenital malformations. This stringent filtering ensured that the developmental assessments were focused specifically on the variable of maternal vaccination rather than external environmental or biological stressors.

Assessing Neurodevelopmental Milestones

The assessment phase of the study was conducted when the children reached the age range of 18 to 30 months. To measure neurodevelopmental progress, the researchers utilized the Ages and Stages Questionnaire (ASQ-3), a validated screening tool designed to capture a child’s progress in five key developmental domains: communication, gross motor skills, fine motor skills, problem-solving, and personal-social interaction.

Beyond the ASQ-3, the research team implemented a suite of behavioral and developmental evaluations to ensure the findings were robust. These included the Child Behavior Checklist, the Modified Checklist for Autism in Toddlers (M-CHAT), and the Early Childhood Behavior Questionnaire. By layering these assessments, the researchers were able to create a multidimensional profile of each child’s development, checking for subtle indicators of neurodivergence or developmental delays that might not be immediately apparent through casual observation.

Senior researcher George R. Saade, MD, who serves as the Professor and Chair of Obstetrics and Gynecology at the Macon & Joan Brock Virginia Health Sciences at Old Dominion University, emphasized the clarity of the results. "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine," Dr. Saade stated. This conclusion underscores the absence of a statistically significant signal that would suggest an increased risk of autism or other developmental pathologies associated with mRNA vaccine technology.

The Broader Context of Maternal Vaccination

The question of vaccine safety during pregnancy is a cornerstone of public health discourse. In the United States, current medical guidance recommends two primary types of COVID-19 vaccines: the mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, and protein subunit vaccines, such as Novavax. These vaccines are widely endorsed by organizations like the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control and Prevention (CDC).

The rationale for these recommendations is multifaceted. Pregnancy is known to be a state of immune modulation, which can increase the severity of respiratory infections. COVID-19 infection during pregnancy has been linked to increased rates of preterm birth, preeclampsia, and intensive care unit admissions for the mother. By receiving the vaccine, pregnant individuals can significantly lower their risk of severe COVID-19, which, in turn, safeguards the developmental environment of the fetus.

Historically, vaccine hesitancy during pregnancy has stemmed from a lack of long-term data. Unlike adult vaccination programs, studies on pregnant populations often take longer to execute due to the necessity of following the child’s development for several years post-birth. The 2026 MFMU study addresses this "information gap" by moving beyond the immediate neonatal outcomes to look at the toddler years, a critical window for identifying neurodevelopmental markers.

Official Responses and Scientific Implications

Brenna L. Hughes, MD, MSc, the Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning at Duke University, noted the importance of the study’s institutional support. "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," she stated.

The participation of the National Institutes of Health (NIH) adds a layer of objective verification to the findings. While the authors acknowledged that the conclusions presented represent their own research and do not necessarily reflect the official views of the NIH, the institutional backing provides the study with a level of clinical legitimacy required to influence future clinical guidelines.

For clinicians, the implications are immediate. The data provides a concrete reference point for obstetricians and midwives when counseling patients who express anxiety about the long-term effects of vaccination. By translating these findings into practice, healthcare providers can offer evidence-based reassurance, potentially reducing the hesitancy that has prevented some pregnant individuals from accessing life-saving preventive care.

Analysis of Future Research Directions

While this study provides a clear "all-clear" regarding autism and developmental delays at the 30-month mark, medical researchers are already looking toward the next phase of longitudinal monitoring. As these children progress into early school age, researchers expect to continue tracking cohorts to ensure that the findings remain consistent as cognitive demands increase.

Furthermore, the focus on mRNA technology provides a blueprint for studying other maternal vaccinations. The success of this study in using the ASQ-3 and other standardized checklists creates a template for future maternal-fetal medicine research. As new vaccines are developed for emerging respiratory threats, the methodologies established by the MFMU network will likely serve as the gold standard for safety evaluations.

The study, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," is scheduled for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed journal of the Society for Maternal-Fetal Medicine. This publication will include the full technical breakdown of the statistical models used to match the cohorts and the detailed data tables for each of the five neurodevelopmental domains assessed.

Summary of Findings and Public Health Impact

The weight of the evidence presented at the 2026 SMFM meeting points to a clear conclusion: there is no evidence-based link between the mRNA COVID-19 vaccine and developmental impairment in children born to vaccinated mothers. In an era of medical misinformation, the availability of peer-reviewed, longitudinal data is the most effective tool for public health advocacy.

By confirming that the vaccination of a pregnant person does not disrupt the intricate process of neurodevelopment, the research allows families to focus on the established benefits of immunization. As society continues to manage the presence of COVID-19, the integration of these findings into standard prenatal care will be essential for maintaining both maternal health and the long-term wellbeing of the next generation. The rigorous, multi-center nature of the study ensures that these results are not an outlier but a representative look at the safety profile of mRNA vaccines, providing a solid foundation for the continued recommendation of these life-saving interventions during pregnancy.